Legend Biotech Past Earnings Performance
Past criteria checks 0/6
Legend Biotech's earnings have been declining at an average annual rate of -15.5%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 47.7% per year.
Key information
-15.5%
Earnings growth rate
-4.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 47.7% |
| Return on equity | -31.2% |
| Net Margin | -66.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Legend Biotech Corporation (NASDAQ:LEGN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 15
Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion
Sep 18Optimistic Investors Push Legend Biotech Corporation (NASDAQ:LEGN) Shares Up 26% But Growth Is Lacking
Aug 01Legend Biotech's Promising CAR-T Therapies Face Valuation And Cash Burn Challenges
Jul 30Rock star Growth Puts Legend Biotech (NASDAQ:LEGN) In A Position To Use Debt
Jul 05Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances
May 14Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio
May 13Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade)
Mar 15Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?
Mar 06Legend Biotech: Solid Traction With Carvykti Rollout
Jan 29Legend Biotech Corporation's (NASDAQ:LEGN) Share Price Not Quite Adding Up
Jan 16Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?
Nov 09Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?
Apr 12An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 44% Undervalued
Dec 14Legend Biotech wins approval of Carvykti for multiple myeloma in Japan
Sep 27Legend Biotech stock slides on proposed ADS offering
Jul 25Legend Biotech ends Phase 1 trial for lymphoma candidate
Jul 07News Flash: Analysts Just Made A Notable Upgrade To Their Legend Biotech Corporation (NASDAQ:LEGN) Forecasts
Jun 05Legend Biotech (NASDAQ:LEGN) Has Debt But No Earnings; Should You Worry?
May 14Here's What Analysts Are Forecasting For Legend Biotech Corporation (NASDAQ:LEGN) After Its Full-Year Results
Mar 22Legend Biotech: Carvykti Approval Makes For A Buy Opportunity
Mar 04Legend Biotech Corporation (NASDAQ:LEGN) Analysts Are More Bearish Than They Used To Be
Mar 03Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?
Dec 30Revenue & Expenses Breakdown
How Legend Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 520 | -348 | 264 | 0 |
| 30 Jun 24 | 456 | -285 | 233 | 0 |
| 31 Mar 24 | 343 | -466 | 217 | 0 |
| 31 Dec 23 | 285 | -518 | 201 | 0 |
| 30 Sep 23 | 233 | -509 | 191 | 0 |
| 30 Jun 23 | 165 | -532 | 184 | 0 |
| 31 Mar 23 | 112 | -517 | 180 | 0 |
| 31 Dec 22 | 117 | -446 | 174 | 0 |
| 30 Sep 22 | 106 | -416 | 192 | -227 |
| 30 Jun 22 | 96 | -457 | 181 | -155 |
| 31 Mar 22 | 119 | -346 | 161 | 313 |
| 31 Dec 21 | 69 | -404 | 150 | 0 |
| 30 Sep 21 | 93 | -356 | 113 | 294 |
| 30 Jun 21 | 89 | -297 | 97 | 285 |
| 31 Mar 21 | 80 | -340 | 85 | 184 |
| 31 Dec 20 | 75 | -266 | 73 | 0 |
| 30 Sep 20 | 59 | -310 | 55 | 231 |
| 30 Jun 20 | 64 | -271 | 46 | 210 |
| 31 Mar 20 | 61 | -165 | 38 | 189 |
| 01 Jan 20 | 62 | -102 | 32 | 162 |
| 31 Dec 18 | 49 | -3 | 4 | 61 |
| 31 Dec 17 | 24 | 9 | 2 | 8 |
Quality Earnings: LEGN is currently unprofitable.
Growing Profit Margin: LEGN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LEGN is unprofitable, and losses have increased over the past 5 years at a rate of 15.5% per year.
Accelerating Growth: Unable to compare LEGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LEGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: LEGN has a negative Return on Equity (-31.19%), as it is currently unprofitable.